Biography
Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine, and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials
Dr Pegram received his medical degree from the University of North Carolina at Chapel Hill. He went on to complete an internship and residency at the University of Texas Southwestern Medical Center in Dallas. He concluded his training with a fellowship at the UCLA David Geffen School of Medicine in Los Angeles, CA.
Dr Pegram’s breast cancer ÌÇÐÄ´«Ã½ is focused on the study of the cancer-associated gene that encodes HER2 and on the development of novel agents in the treatment of patients with HER2-positive metastatic breast cancer. Dr Pegram has been educating other healthcare professionals about the future impact of biosimilars in oncology practice, especially in the breast cancer treatment landscape. He has authored more than 110 publications in medical oncology, hematology, and biosimilars across different cancer types.
Dr Pegram received his medical degree from the University of North Carolina at Chapel Hill. He went on to complete an internship and residency at the University of Texas Southwestern Medical Center in Dallas. He concluded his training with a fellowship at the UCLA David Geffen School of Medicine in Los Angeles, CA.
Dr Pegram’s breast cancer ÌÇÐÄ´«Ã½ is focused on the study of the cancer-associated gene that encodes HER2 and on the development of novel agents in the treatment of patients with HER2-positive metastatic breast cancer. Dr Pegram has been educating other healthcare professionals about the future impact of biosimilars in oncology practice, especially in the breast cancer treatment landscape. He has authored more than 110 publications in medical oncology, hematology, and biosimilars across different cancer types.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2024)
- Fellowship: UCLA Division of Hematology and Oncology (1993) CA
- Residency: University of Texas Southwestern Internal Medicine Residency (1990) TX
-
- Medical Education: University of North Carolina School of Medicine (1986) NC
- Board Certification: American Board of Internal Medicine, Internal Medicine (1989)
Honors & Awards
- 2012 Keynote Lecture, American Radium Society 94th Annual Meeting, American Radium Society (29 April 2012)
- 6th Annual Connie Moskow Memorial Lectureship, Robert H. Lurie Comprehensive Cancer Center of Northwestern University (11 May 2012)
- Chair, Department of Defense Breast Cancer Research Program Integration Panel, Congressionally Directed Medical Research Programs, U.S. Army Research and Materiel Command (2012)
-
- John G. Kuhn Lecture, Hematology/Oncology Pharmacy Association (21 March 2013)
- Sylvester Outstanding Cancer Research Award, University of Miami Sylvester Comprehensive Cancer Center (13 May 2011)
- The Celebrity Cruises Award, The Breast Cancer Research Foundation (2013-2014)
Administrative Appointments
- Associate Dean for Clinical Research Quality, Stanford School of Medicine (2018 - Present)
- Associate Director for Clinical Research, Stanford Cancer Institute (2013 - Present)
- Co-Director, Translational Oncology Research Program @ Stanford (TOP@S), Stanford Cancer Institute (2013 - 2018)
-
- Director, Stanford Breast Oncology Program, Stanford Cancer Institute (2012 - 2019)
- Medical Director of the Stanford Clinical Translational Research Unit, Stanford School of Medicine (2020 - Present)
Publications
-
HER-2/neu as a predictive marker of response to breast cancer therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998). HER-2/neu as a predictive marker of response to breast cancer therapy. BREAST CANCER RESEARCH AND TREATMENT, 52(1-3), 65–77. -
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
Pegram, M. D., & Slamon, D. J. (1999). Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. SEMINARS IN ONCOLOGY, 26(4), 89–95. -
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
Aguilar, Z., Akita, R. W., Finn, R. S., Ramos, B. L., Pegram, M. D., Kabbinavar, F. F., … Slamon, D. J. (1999). Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. ONCOGENE, 18(44), 6050–6062. -
-
A model-based approach for assessing in vivo combination therapy interactions
Lopez, A. M., Pegram, M. D., Slamon, D. J., & Landaw, E. M. (1999). A model-based approach for assessing in vivo combination therapy interactions. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 96(23), 13023–13028. -
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Pegram, M. D., Konecny, G., & Slamon, D. J. (2000). The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treatment and Research, 103, 57–75. -
Trastuzumab and chemotherapeutics: Drug interactions and synergies
Pegram, M. D., Lopez, A., Konecny, G., & Slamon, D. J. (2000). Trastuzumab and chemotherapeutics: Drug interactions and synergies. SEMINARS IN ONCOLOGY, 27(6), 21–25. -
Docetaxel and Herceptin: Foundation for future strategies
Pegram, M. D. (2001). Docetaxel and Herceptin: Foundation for future strategies. Presented at the Symposium on Innovative Therapies in Breast Cancer, VALLETTA,MALTA: ALPHAMED PRESS. -
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Pegram, M. D., & O'Callaghan, C. (2001). Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. Clinical Breast Cancer, 2, S15–9. -
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor
Pegram, M. D., & Reese, D. M. (2002). Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. SEMINARS IN ONCOLOGY, 29(3), 29–37. -
Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.
Gilbert, C. W., McGowan, E. B., Seery, G. B., Black, K. S., & Pegram, M. D. (2003). Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker. Journal of Experimental Therapeutics & Oncology, 3(1), 27–35. -
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H. J., Bauerfeind, I., Epstein, M., … Pegram, M. D. (2004). Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. CLINICAL CANCER RESEARCH, 10(5), 1706–1716. -
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004). Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 96(10), 739–749. -
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., … Slamon, D. J. (2004). Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 96(10), 759–769. -
HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
Konecny, G. E., Thomssen, C., Luck, H. J., Untch, M., Wang, H. J., Kuhn, W., … Slamon, D. J. (2004). HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 96(15), 1141–1151. -
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny, G. E., & Pegram, M. D. (2004). Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Williston Park, N.Y.), 18(14), 32–36. -
Targeted therapy: Wave of the future
Pegram, M. D., Pietras, R., Bajamonde, A., Klein, P., & Fyfe, G. (2005). Targeted therapy: Wave of the future. JOURNAL OF CLINICAL ONCOLOGY, 23(8), 1776–1781. -
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Yeon, C. H., & Pegram, M. D. (2005). Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 391–409. -
Image-detected breast cancer: State of the art diagnosis and treatment
Silverstein, M. J., Lagios, M. D., Recht, A., Allred, D. C., Harms, S. E., Holland, R., … Whitworth, P. W. (2005). Image-detected breast cancer: State of the art diagnosis and treatment. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 201(4), 586–97. -
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with F-18-fluoropaclitaxel
Gangloff, A., Hsueh, W. A., Kesner, A. L., Kiesewetter, D. O., Pio, B. S., Pegram, M. D., … Silverman, D. H. S. (2005). Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with F-18-fluoropaclitaxel. JOURNAL OF NUCLEAR MEDICINE, 46(11), 1866–1871. -
Usefulness of 3 '-[F-18]fluoro-3 '-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy
Pio, B. S., Park, C. K., Pietras, R., Hsueh, W. A., Satyamurthy, N., Pegram, M. D., … Silverman, D. H. S. (2006). Usefulness of 3 '-[F-18]fluoro-3 '-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. MOLECULAR IMAGING AND BIOLOGY, 8(1), 36–42. -
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
Ryan, B. M., Konecny, G. E., Kahlert, S., Wang, H. J., Untch, M., Meng, G., … Duffy, M. J. (2006). Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. ANNALS OF ONCOLOGY, 17(4), 597–604. -
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G. R., Rahmeh, M., … Slamon, D. J. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. CANCER RESEARCH, 66(3), 1630–1639. -
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., … Slamon, D. J. (2006). Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(12), 1831–1838. -
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., Fleming, G. F., … Karlan, B. Y. (2006). Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. JOURNAL OF CLINICAL ONCOLOGY, 24(26), 4324–4332. -
Predicting chemotherapy response to paclitaxel with F-18-fluoropaclitaxel and PET
Hsueh, W.-A., Kesner, A. L., Gangloff, A., Pegram, M. D., Beryt, M., Czernin, J., … Silverman, D. H. S. (2006). Predicting chemotherapy response to paclitaxel with F-18-fluoropaclitaxel and PET. JOURNAL OF NUCLEAR MEDICINE, 47(12), 1995–1999. -
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., … Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(1), 118–145. -
Biodistribution and predictive value of (IF)-I-18-fluorocyclophosphamide in mice bearing human breast cancer xenografts
Kesner, A. L., Hsueh, W.-A., Htet, N. L., Pio, B. S., Czernin, J., Pegram, M. D., … Silverman, D. H. S. (2007). Biodistribution and predictive value of (IF)-I-18-fluorocyclophosphamide in mice bearing human breast cancer xenografts. JOURNAL OF NUCLEAR MEDICINE, 48(12), 2021–2027. -
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer
Storniolo, A. M., Pegram, M. D., Overmoyer, B., Silverman, P., Peacock, N. W., Jones, S. F., … Burris, H. A. (2008). Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(20), 3317–3323. -
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., … Burstein, H. J. (2009). Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. ANNALS OF ONCOLOGY, 20(6), 1026–1031. -
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., … Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 131(1), 18–43. -
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
Pegram, M. D., Borges, V. F., Ibrahim, N., Fuloria, J., Shapiro, C., Perez, S., … Luck, N. C. (2009). Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. BREAST CANCER RESEARCH, 11(5). -
Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.
Harbeck, N., Pegram, M. D., Rüschoff, J., & Möbus, V. (2010). Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast Care (Basel, Switzerland), 5(s1), 3–7. -
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., … Slamon, D. J. (2011). Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. JOURNAL OF CLINICAL ONCOLOGY, 29(2), 149–156. -
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis
Houssami, N., Macaskill, P., Balleine, R. L., Bilous, M., & Pegram, M. D. (2011). HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. BREAST CANCER RESEARCH AND TREATMENT, 129(3), 659–674. -
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer
Smith, T. R., Liu-Mares, W., Van Emburgh, B. O., Levine, E. A., Allen, G. O., Hill, J. W., … Hu, J. J. (2011). Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. CARCINOGENESIS, 32(9), 1354–1360. -
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., … Glueck, S. (2012). Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 132(1), 215–223. -
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.
Ward, T. M., IORNS, E., Liu, X., Hoe, N., Kim, P., Singh, S., … Pegram, M. D. (2013). Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene, 32(19), 2463–2474. -
Tumor Biology Trumps Anatomy in Breast Cancer Brain Metastases
Pegram, M. D. (2012). Tumor Biology Trumps Anatomy in Breast Cancer Brain Metastases. ONCOLOGY-NEW YORK, 26(7), 666-? -
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells
Jegg, A.-M., Ward, T. M., Iorns, E., Hoe, N., Zhou, J., Liu, X., … Pegram, M. D. (2012). PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 683–692. -
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference
Toi, M., Benson, J. R., Winer, E. P., Forbes, J. F., von Minckwitz, G., Golshan, M., … Inamoto, T. (2012). Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 919–926. -
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Hurley, J., Reis, I. M., Rodgers, S. E., Gomez-Fernandez, C., Wright, J., Leone, J. P., … Pegram, M. D. (2013). The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Research and Treatment, 138(3), 783–794. -
DIAGNOSIS OF INFECTIVE AND INFLAMMATORY DISORDERS BY FLOW CYTOMETRIC ANALYSIS OF BLOOD NEUTROPHILS
Bentley, S. A., Pegram, M. D., & Ross, D. W. (1987). DIAGNOSIS OF INFECTIVE AND INFLAMMATORY DISORDERS BY FLOW CYTOMETRIC ANALYSIS OF BLOOD NEUTROPHILS. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 88(2), 177–181. -
HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS
Pietras, R. J., Arboleda, J., Reese, D. M., WONGVIPAT, N., Pegram, M. D., Ramos, L., … Slamon, D. J. (1995). HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS. ONCOGENE, 10(12), 2435–2446. -
ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS
Pietras, R. J., Fendly, B. M., CHAZIN, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994). ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS. ONCOGENE, 9(7), 1829–1838. -
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. ONCOGENE, 15(5), 537–547. -
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., … Slamon, D. J. (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. JOURNAL OF CLINICAL ONCOLOGY, 16(8), 2659–2671. -
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. ONCOGENE, 17(17), 2235–2249. -
Comprehensive molecular portraits of human breast tumours
Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F., … Palchik, J. D. (2012). Comprehensive molecular portraits of human breast tumours. NATURE, 490(7418), 61–70. -
HER-2/neu as a predictive marker in breast cancer
Konecny, G., Pegram, M., Untch, M., Thomssen, C., JANICKE, F., Hepp, H., & Slamon, D. J. (2000). HER-2/neu as a predictive marker in breast cancer. GEBURTSHILFE UND FRAUENHEILKUNDE, 60(12), 609–619. -
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
Pegram, M., HSU, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., … Slamon, D. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. ONCOGENE, 18(13), 2241–2251. -
Docetaxel and trastuzumab: A combination with clinical relevance
Konecny, G., Pegram, M., & Slamon, D. (2000). Docetaxel and trastuzumab: A combination with clinical relevance. Presented at the Symposium on a New Era in Oncology, STRASBOURG,FRANCE: KARGER. -
Treating the HER2 Pathway in Early and Advanced Breast Cancer
Pegram, M. D. (2013). Treating the HER2 Pathway in Early and Advanced Breast Cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 27(4), 751-? -
Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., … Kumar, R. (2014). Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(4), 542–90. -
Assessing the Discordance Rate Between Local and Central HER2 Testing in Women With Locally Determined HER2-Negative Breast Cancer
Kaufman, P. A., Bloom, K. J., Burris, H., Gralow, J. R., Mayer, M., Pegram, M., … Vogel, C. L. (2014). Assessing the Discordance Rate Between Local and Central HER2 Testing in Women With Locally Determined HER2-Negative Breast Cancer. CANCER, 120(17), 2657–2664. -
Herceptin in the treatment of metastatic breast cancer
Konecny, G., Untch, M., & Pegram, M. (1999). Herceptin in the treatment of metastatic breast cancer. GYNAKOLOGE, 32(8), 624–31. -
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., … Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEW ENGLAND JOURNAL OF MEDICINE, 344(11), 783–92. -
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
Slamon, D., & Pegram, M. (2001). Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. SEMINARS IN ONCOLOGY, 28(1), 13–19. -
Breast cancer version 3.2014.
Gradishar, W. J., Anderson, B. O., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., … Kumar, R. (2014). Breast cancer version 3.2014. Journal of the National Comprehensive Cancer Network , 12(4), 542–90. -
HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer
Konecny, G., Untch, M., Arboleda, J., Wilson, C., Kahlert, S., Boettcher, B., … Pegram, M. (2001). HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. CLINICAL CANCER RESEARCH, 7(8), 2448–57. -
A human ovarian carcinoma murine xenograft model useful for preclinical trials
Elkas, J. C., Baldwin, R. L., Pegram, M., Tseng, Y., Slamon, D., & Karlan, B. Y. (2002). A human ovarian carcinoma murine xenograft model useful for preclinical trials. GYNECOLOGIC ONCOLOGY, 87(2), 200–206. -
Proceedings of the First Global Workshop on Breast Cancer: Pathways to the Evaluation and Clinical Development of Novel Agents for Breast Cancer
Albain, K. S., Carey, L., Gradishar, W. J., Gralow, J. R., Lipton, A., Rugo, H., … Pegram, M. (2010). Proceedings of the First Global Workshop on Breast Cancer: Pathways to the Evaluation and Clinical Development of Novel Agents for Breast Cancer. CLINICAL BREAST CANCER, 10(6), 421–39. -
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
Pegram, M., & Slamon, D. (2000). Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. SEMINARS IN ONCOLOGY, 27(5), 13–19. -
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy
Crown, J., & Pegram, M. (2003). Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. BREAST CANCER RESEARCH AND TREATMENT, 79, S11–S18. -
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples
Konecny, G., Untch, M., Slamon, D., Beryt, M., Kahlert, S., Felber, M., … Pegram, M. (2001). Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. BREAST CANCER RESEARCH AND TREATMENT, 67(3), 223–33. -
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer
Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., … Pegram, M. (2001). Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. CLINICAL CANCER RESEARCH, 7(6), 1743–49. -
Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., … Slamon, D. J. (2003). Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95(2), 142–53. -
Lapatinib: new opportunities for management of breast cancer.
Liao, J., Gallas, M., Pegram, M., & Slingerland, J. (2010). Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Medical Press), 2, 79–91. -
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
Konecny, G., FRITZ, M., Untch, M., Lebeau, A., Felber, M., Lude, S., … Pegram, M. (2001). HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 69(1), 53–63. -
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta 1
Landgraf, R., Pegram, M., Slamon, D. J., & Eisenberg, D. (1998). Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta 1. BIOCHEMISTRY, 37(9), 3220–28. -
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase
Lackey, D. B., Groziak, M. P., Sergeeva, M., Beryt, M., Boyer, C., Stroud, R. M., … Pegram, M. (2001). Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. BIOCHEMICAL PHARMACOLOGY, 61(2), 179–89. -
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., … Pegram, M. (2009). Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(33), 5538–46. -
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500
Buller, R. E., Shahin, M. S., Horowitz, J. A., Runnebaum, I. B., Mahavni, V., Petrauskas, S., … Pegram, M. (2002). Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. CANCER GENE THERAPY, 9(7), 567–72. -
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
Royer, B., Yin, W., Pegram, M., Ibrahim, N., Villanueva, C., Mir, D., … Pivot, X. (2010). Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. BRITISH JOURNAL OF CANCER, 102(5), 827–32. -
Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.
Emmanouilides, C., Pegram, M., Robinson, R., Hecht, R., Kabbinavar, F., & Isacoff, W. (2004). Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Techniques in Coloproctology, 8, s50–2. -
Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies
Nguyen, M., Tran, C., Barsky, S., Sun, J. R., McBride, W., Pegram, M., … Glaspy, J. (1997). Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies. INTERNATIONAL JOURNAL OF ONCOLOGY, 10(5), 965–69. -
Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Ibrahim, N. K., Yariz, K. O., Bondarenko, I., Manikhas, A., Semiglazov, V., Alyasova, A., … Pegram, M. (2011). Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. CLINICAL CANCER RESEARCH, 17(21), 6822–30. -
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin((R))): A case study
Pegram, M., & Ngo, D. (2006). Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin((R))): A case study. ADVANCED DRUG DELIVERY REVIEWS, 58(5-6), 723–34. -
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., … Blackwell, K. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 367(19), 1783–91. -
Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas
MacGrogan, D., Pegram, M., Slamon, D., & Bookstein, R. (1997). Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. ONCOGENE, 15(9), 1111–14. -
Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions
Pegram, M., & Liao, J. (2012). Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions. CLINICAL BREAST CANCER, 12(1), 10–18. -
Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer
Araki, K., Saji, S., Gallas, M., Pegram, M., & Sasaki, Y. (2012). Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer. BREAST CANCER, 19(2), 95–103. -
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?
Pegram, M. (2008). Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? CLINICAL BREAST CANCER, 8, S121–S130. -
Association Studies of Fc gamma Receptor Polymorphisms with Outcome in HER2(+) Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
Norton, N., Olson, R. M., Pegram, M., Tenner, K., Ballman, K. V., Clynes, R., … Perez, E. A. (2014). Association Studies of Fc gamma Receptor Polymorphisms with Outcome in HER2(+) Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. CANCER IMMUNOLOGY RESEARCH, 2(10), 962–69. -
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer
Konecny, G., Crohns, C., Pegram, M., Felber, M., Lude, S., Kurbacher, C., … Untch, M. (2000). Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. GYNECOLOGIC ONCOLOGY, 77(2), 258–63. -
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy
Pal, S. K., & Pegram, M. (2005). Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. ANTI-CANCER DRUGS, 16(5), 483–94. -
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor
Iorns, E., Ward, T. M., Dean, S., Jegg, A., Thomas, D., Murugaesu, N., … Lippman, M. (2012). Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. BREAST CANCER RESEARCH AND TREATMENT, 135(1), 79–91. -
Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction
Neuteboom, S. T. C., Karjian, P. L., Boyer, C. R., Beryt, M., Pegram, M., Wahl, G. M., & SHEPARD, H. M. (2002). Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction. MOLECULAR CANCER THERAPEUTICS, 1(6), 377–84. -
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer
Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Buekers, T., … Pegram, M. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. CANCER GENE THERAPY, 9(7), 553–66. -
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents
Holash, J., Thurston, G., Rudge, J. S., Yancopoulos, G. D., Adjei, A. A., Bergers, G., … Gordon, M. S. (2006). Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. CANCER AND METASTASIS REVIEWS, 25(2), 243–52. -
Personalization of loco-regional care for primary breast cancer patients (part 1)
Toi, M., Winer, E. P., Benson, J. R., Inamoto, T., Forbes, J. F., von Minckwitz, G., … Klimberg, V. S. (2015). Personalization of loco-regional care for primary breast cancer patients (part 1). FUTURE ONCOLOGY, 11(9), 1297–1300. -
Personalization of loco-regional care for primary breast cancer patients (part 2)
Toi, M., Winer, E. P., Benson, J. R., Inamoto, T., Forbes, J. F., von Minckwitz, G., … Klimberg, V. S. (2015). Personalization of loco-regional care for primary breast cancer patients (part 2). FUTURE ONCOLOGY, 11(9), 1301–5. -
Reducing the global breast cancer burden: the importance of patterns of care ÌÇÐÄ´«Ã½.
Albain, K. S., De la Garza Salazar, J., Pienkowski, T., Aapro, M., Bergh, J., Caleffi, M., … Hortobagyi, G. N. (2005). Reducing the global breast cancer burden: the importance of patterns of care ÌÇÐÄ´«Ã½. Clinical Breast Cancer, 6(5), 412–20. -
"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.
Sledge, G. W., & Pegram, M. D. (2015). "Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic. Clinical Cancer Research , 21(12), 2663–65. -
Everything old is neu again: cellular senescence in HER2-positive breast cancer.
Sledge, G. W., & Pegram, M. D. (2015). Everything old is neu again: cellular senescence in HER2-positive breast cancer. Journal of the National Cancer Institute, 107(5). -
Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting
Duncombe, T. A., Kang, C.-C., Maity, S., Ward, T. M., Pegram, M. D., Murthy, N., & Herr, A. E. (2016). Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting. ADVANCED MATERIALS, 28(2), 327–34. -
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M., Guardino, E., Althaus, B., … Elias, A. (2016). Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research , 18(1), 34-? -
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M., Guardino, E., Althaus, B., … Elias, A. (2016). Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. BREAST CANCER RESEARCH, 18. -
Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Liu, J., Chen, X., Ward, T., Mao, Y., Bockhorn, J., Liu, X., … Shen, K. (2016). Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. International Journal of Biochemistry & Cell Biology, 71, 12–23. -
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology
Che, J., Yu, V., Dhar, M., Renier, C., Matsumoto, M., Heirich, K., … Di Carlo, D. (2016). Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. ONCOTARGET, 7(11), 12748–60. -
Improved Survival of HER2(+) Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
Knutson, K. L., Clynes, R., Shreeder, B., Yeramian, P., Kemp, K. P., Ballman, K., … Perez, E. A. (2016). Improved Survival of HER2(+) Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. CANCER RESEARCH, 76(13), 3702–10. -
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Baselga, J., Lewis Phillips, G. D., Verma, S., Ro, J., Huober, J., Guardino, A. E., … Pegram, M. D. (2016). Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research , 22(15), 3755–63. -
Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer
Liu, J., Chen, X., Ward, T., Pegram, M., & Shen, K. (2016). Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. TUMOR BIOLOGY, 37(7), 9825–35. -
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., … Ellis, M. J. (2017). Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation.
Wang, J.-H., Forterre, A. V., Zhao, J., Frimannsson, D. O., Delcayre, A., Antes, T. J., … Matin, A. C. (2018). Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation. Molecular Cancer Therapeutics. -
Targeted disruption of transcriptional effector GLI2 attenuates breast tumor growth and metastasis
Beachy, P., Cai, S., Ma, Y., Hatakeyama, J., Zhao, C., Stoffels, M., … Pegram, M. (2018). Targeted disruption of transcriptional effector GLI2 attenuates breast tumor growth and metastasis. CANCER RESEARCH, 78(4). -
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)
Abraham, J., Caldera, H., Coleman, R., Elias, A., Goetz, M. P., Kittaneh, M., … Vogel, C. (2018). Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). BREAST CANCER RESEARCH AND TREATMENT, 169(1), 1–7. -
Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution
Kang, C.-C., Ward, T. M., Bockhorn, J., Schiffman, C., Huang, H., Pegram, M. D., & Herr, A. E. (2018). Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. NPJ PRECISION ONCOLOGY, 2, 10. -
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
Norton, N., Fox, N., McCarl, C.-A., Tenner, K. S., Ballman, K., Erskine, C. L., … Knutson, K. L. (2018). Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. BREAST CANCER RESEARCH, 20, 52. -
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
Abraham, J., Coleman, R., Elias, A., Holmes, F. A., Kalinsky, K., Kittaneh, M., … Vogel, C. (2018). Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). BREAST CANCER RESEARCH AND TREATMENT, 171(1), 11–20. -
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., & Moulder, S. L. (2018). Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (38), 65–77. -
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Pegram, M. D., Bondarenko, I., Zorzetto, M. M., Hingmire, S., Iwase, H., Krivorotko, P. V., … Tan-Chiu, E. (2018). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer. -
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802018. -
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Bakre, M. M., Ramkumar, C., Attuluri, A. K., Basavaraj, C., Prakash, C., Buturovic, L., … Pegram, M. D. (2019). Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. Cancer Medicine. -
Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting.
Duncombe, T. A., Kang, C.-C. C., Maity, S., Ward, T. M., Pegram, M. D., Murthy, N., & Herr, A. E. (2016). Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting. Advanced Materials (Deerfield Beach, Fla.), 28(2), 327–334. -
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(12), 946-+. -
High caveolin-1 expression in African American women with early-stage triple-negative breast cancer
Baumbach-Reardon, L. L., Getz, J., Ahearn, M. E., Carpten, J., & Pegram, M. (2018). High caveolin-1 expression in African American women with early-stage triple-negative breast cancer. CANCER RESEARCH, 78(13). -
Induced Pluripotent Stem Cells as a Novel Cancer Vaccine.
Wang, L., Pegram, M. D., & Wu, J. C. (2019). Induced Pluripotent Stem Cells as a Novel Cancer Vaccine. Expert Opinion on Biological Therapy. -
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients
Bakre, M. M., Ramkumar, C., Attuluri, A. K., Basavaraj, C., Prakash, C., Buturovic, L., … Pegram, M. D. (2019). Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. CANCER MEDICINE, 8(4), 1755–64. -
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Pivot, X., Pegram, M., Cortes, J., Lüftner, D., Lyman, G. H., Curigliano, G., … Kim, C. (2019). Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. European Journal of Cancer (Oxford, England : 1990), 120, 1–9. -
HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors.
Pegram, M. D., Miles, D., Tsui, C. K., & Zong, Y. (2019). HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) plus chemotherapy (C) versus trastuzumab (T) plus C in patients (pts) with HER2+metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
Rugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., … Gradishar, W. J. (2019). SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) plus chemotherapy (C) versus trastuzumab (T) plus C in patients (pts) with HER2+metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.
Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Lyman, G. H., Curigliano, G., … Lim, J. Y. (2019). Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.
O'Shaughnessy, J., Piccart, M., Schwartzberg, L. S., Cortes, J., Harbeck, N., Im, S.-A., … Seidman, A. D. (2019). CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus ) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., … Winer, E. P. (2019). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine. -
Extracellular vesicle-mediated in vitro transcribed mRNA delivery for treatment of HER2+ breast cancer xenografts in mice by prodrug CB1954 without general toxicity.
Forterre, A. V., Wang, J.-H. H., Delcayre, A., Kim, K., Green, C., Pegram, M. D., … Matin, A. C. (2020). Extracellular vesicle-mediated in vitro transcribed mRNA delivery for treatment of HER2+ breast cancer xenografts in mice by prodrug CB1954 without general toxicity. Molecular Cancer Therapeutics. -
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Kittaneh, M., Badve, S., Caldera, H., Coleman, R., Goetz, M. P., Mahtani, R., … Vogel, C. (2020). Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer. -
Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
Stebbing, J., Mainwaring, P. N., Curigliano, G., Pegram, M., Latymer, M., Bair, A. H., & Rugo, H. S. (2020). Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1902953. -
Immune cell repertoires in breast cancer patients after adjuvant chemotherapy.
Gustafson, C. E., Jadhav, R., Cao, W., Qi, Q., Pegram, M., Tian, L., … Goronzy, J. J. (2020). Immune cell repertoires in breast cancer patients after adjuvant chemotherapy. JCI Insight, 5(4). -
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Mahtani, R., Holmes, F.-A. A., Badve, S., Caldera, H., Coleman, R., Mamounas, E., … Vogel, C. (2019). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer. -
Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
Rugo, H. S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., … Gradishar, W. J. (2020). Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. CANCER RESEARCH, 80(4). -
Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
Murthy, R., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S., … Winer, E. (2020). Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB). CANCER RESEARCH, 80(4). -
Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study
Lin, N. U., Kumthekar, P., Sahebjam, S., Ibrahim, N., Fung, A., Cheng, A., … Pegram, M. (2020). Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study. CANCER RESEARCH, 80(4). -
Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results
Gradishar, W. J., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., … Rugo, H. S. (2020). Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results. CANCER RESEARCH, 80(4). -
CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
O'Shaughnessy, J., Piccart, M., Schwartzberg, L., Cortes, J., Harbeck, N., Im, S.-A., … Seidman, A. (2020). CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane. CANCER RESEARCH, 80(4). -
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels.
Barfield, R. M., Kim, Y. C., Chuprakov, S., Zhang, F., Bauzon, M., Ogunkoya, A. O., … Drake, P. M. (2020). A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels. Molecular Cancer Therapeutics. -
Intratumoral HER2 heterogeneity in breast cancer.
Pegram, M. (2020). Intratumoral HER2 heterogeneity in breast cancer. Clinical Advances in Hematology & Oncology : H&O, 18(9), 535–37. -
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC).
Escriva, S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Gradishar, W. J., … Rugo, H. S. (2020). SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.
Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Rugo, H. S., Lyman, G. H., … Kim, C. (2020). Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice.
Cui, L., Gouw, A. M., LaGory, E. L., Guo, S., Attarwala, N., Tang, Y., … Rao, J. (2020). Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nature Biotechnology. -
PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY
Kumthekar, P., Sahebjam, S., Pegram, M., Ibrahim, N., Sussell, J., Nicholas, A., … Lin, N. U. (2020). PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY. NEURO-ONCOLOGY, 22, 174–75. -
Intratumoral HER2 Heterogeneity in Breast Cancer
Pegram, M. (2020). Intratumoral HER2 Heterogeneity in Breast Cancer. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 18(9), 535–37. -
Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.
Fernandes, L. E., Epstein, C. G., Bobe, A. M., Bell, J. S., Stumpe, M. C., Salazar, M. E., … Palmer, G. A. (2020). Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. Clinical Breast Cancer. -
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo, H. S., Im, S.-A. A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., … Gradishar, W. J. (2021). Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology. -
RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.
van de Stolpe, A., Verhaegh, W., Blay, J.-Y., Ma, C. X., Pauwels, P., Pegram, M., … Husain, H. (2020). RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. Frontiers in Genetics, 11, 598118. -
PHASE 1/2 STUDY OF NOVEL HER2-TARGETING, TLR7/8 IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) BDC-1001 WITH OR WITHOUT IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS
Sharma, M., Dumbrava, E. I., Carvajal, R., Catenacci, D., Emens, L., Hanna, G., … Perez, E. (2020). PHASE 1/2 STUDY OF NOVEL HER2-TARGETING, TLR7/8 IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) BDC-1001 WITH OR WITHOUT IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8, A244. -
Humanized anti-CD47 monoclonal antibody magrolimab (Hu5F9-G4) plus trastuzumab potentiates antibody-dependent cellular phagocytosis (ADCP), and cooperate to inhibit human HER2+breast cancer (BC) xenografts growth in vivo
Upton, R., Feng, D., Banuelos, A. M., Biswas, T., Willingham, S., Kao, K. S., … Weissman, I. L. (2021). Humanized anti-CD47 monoclonal antibody magrolimab (Hu5F9-G4) plus trastuzumab potentiates antibody-dependent cellular phagocytosis (ADCP), and cooperate to inhibit human HER2+breast cancer (BC) xenografts growth in vivo. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Health-related quality of life for margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+metastatic breast cancer
Cardoso, F., Cortes, J., Gradishar, W., Im, S.-A., Pegram, M. D., Rugo, H. S., … Curigliano, G. (2021). Health-related quality of life for margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+metastatic breast cancer. CANCER RESEARCH, 81(4). -
Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H. S., Yardley, D. A., Cortes, J., … Seidman, A. (2021). Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane. CANCER RESEARCH, 81(4). -
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Dumbrava, E. I., Sharma, M. R., Carvajal, R. D., Catenacci, D., Emens, L. A., Gadgeel, S. M., … Perez, E. A. (2021). Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. CANCER RESEARCH, 81(4). -
Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer
Aftimos, P., Maglakelidze, M., Glaudemans, A. W. J. M., Hamilton, E., Chap, L., de Vries, E., … Sorrentino, J. A. (2021). Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer. CANCER RESEARCH, 81(4). -
Infusion related reactions in the phase 3 SOPHIA trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with pretreated HER2+metastatic breast cancer
Cortes, J., Cardoso, F., Curigliano, G., Gradishar, W. J., Im, S.-A., Rugo, H. S., … Pegram, M. D. (2021). Infusion related reactions in the phase 3 SOPHIA trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with pretreated HER2+metastatic breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
cGAS-STING pathway protein expression in human primary breast cancer
Zong, Y., Liu, X., Barber, G. N., & Pegram, M. D. (2021). cGAS-STING pathway protein expression in human primary breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)
Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Rugo, H. S., … Gradishar, W. J. (2021). Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2-locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection
Aftimos, P., Neven, P., Pegram, M., van Oord, C. W. M.-van der H., Dees, E. C., Schroder, C., … Jain, S. (2021). Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2-locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani, R., Kittaneh, M., Kalinsky, K., Mamounas, E., Badve, S., Vogel, C., … Pegram, M. (2020). Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clinical Breast Cancer. -
Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane
O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H. S., Yardley, D. A., Cortes, J., … Seidman, A. (2021). Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19(2), 12–13. -
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
Lin, N. U., Pegram, M., Sahebjam, S., Ibrahim, N., Fung, A., Cheng, A., … Kumthekar, P. (2021). Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2002822. -
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2+ Advanced Breast or Gastric Cancer.
Pegram, M. D., Hamilton, E. P., Tan, A. R., Storniolo, A. M., Balic, K., Rosenbaum, A. I., … Patel, M. R. (2021). First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2+ Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics. -
Biosimilars in an era of rising oncology treatment options.
Peeters, M., Planchard, D., Pegram, M., Goncalves, J., Bocquet, F., Jang, H., & Kim, D. (2021). Biosimilars in an era of rising oncology treatment options. Future Oncology (London, England). -
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton, R., Banuelos, A., Feng, D., Biswas, T., Kao, K., McKenna, K., … Weissman, I. L. (2021). Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences of the United States of America, 118(29). -
Single-cell immunoblotting resolves estrogen receptor-alpha isoforms in breast cancer.
Kim, J. J., Liang, W., Kang, C.-C., Pegram, M. D., & Herr, A. E. (2021). Single-cell immunoblotting resolves estrogen receptor-alpha isoforms in breast cancer. PloS One, 16(7), e0254783. -
A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER.
Ma, C. X., Luo, J., Freedman, R. A., Pluard, T., Nangia, J., Lu, J., … Bose, R. (2021). A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
-
A model-based approach for assessing in vivo combination therapy interactions
Clinical Trials
Clinical trials are ÌÇÐÄ´«Ã½ studies that evaluate a new medical approach, device, drug, or other treatment. As a ÌÇÐÄ´«Ã½ patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)
- A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
- A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
- Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
- Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
Practice Locations
Stanford Women's Cancer Center Palo Alto, CA
Palo Alto, CA
Stanford Women's Cancer Center
900 Blake Wilbur Dr, Fl 1
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereCancer Immunotherapy Program Palo Alto, CA
Palo Alto, CA
Cancer Immunotherapy Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereBreast Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Breast Cancer Program in Palo Alto
900 Blake Wilbur Dr, Fl 1
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri- Valley, or Stanford Medicine Partners. ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(49 reviews)
Dr. Pegram is an asset to Stanford. He is professional, attentive, supportive and courteous.
Dr. Pegram is outstanding. I feel lucky to have him as my doctor.
I would like more explaining of tx, but his schedule was heavy & I am not in crisis right now.
Exceptionally good.
Excellent information.
Dr. Pegram is like an angle!!!
Dr. Pegram was amazing - Consultation only. Not continuing care.
Dr. Pegram is a true professional. He relaxes you and is very knowledgeable. He explains things in laymans language.
I feel I am in the best care with Dr. Pegram.
Love Dr. Pegram.
A very exceptionally good dr. and medical team - great team!
Always a pleasure. I felt privileged to see Dr. Pegram
Excellent knowledge/advice, communication, etc. I am very thankful for the consult.
I really like my Dr. Mark Pegram. He was very friendly and down to Earth.
Dr. Pegram is an excellent communicator.
Excellent experience: Dr. Pegram was attentive to my questions/concerns & in addressing them, he also clearly presented the relevant considerations informing his decision/answer. [Also - Dr. Graber (resident) was very thorough & patient.]
I feel fortunate to have Dr. Pegram as my doctor.
I ADORE Dr. Pegram and his staff and fly from Idaho to be under his care!!!
Extremely happy with my care with Dr. Pegram, Nicole Barr and staff.
Dr. Pegram is busy but when he see me. I get his full attention & would not rush me. He listen. He only get up when I say I'm fine.
Dr. Pegram is good, care of his patient and always answer all my questions & concern. I feel confident to have him as my care provider and will recommend to anyone I know needs his care.
Dr. Pegram and his PA are always attentive and thorough during my appointments.
Dr. Pegram is outstanding, he is busy but made sure that he is with you 100% when I am with him for consultation. He listen & has answers.
My experience with Mark Pegram and his staff has been excellent.
Dr. Pegram is a wonderful doctor. So kind and caring. He is held in high regard by my entire team in Ann Arbor, Michigan.
Dr. Pegram is awesome. Yes I would highly recommend him.
Very professional.
Dr. Pegram is the BEST!!
Dr. Paul & Dr. Pegram were wonderful. I made my surgery decision based on what Dr. Pegram said. He inspired confidence.
Dr. Pegram is thorough in his analysis & approach and candid in his explanations. He shows compassion & concern and provides alternatives for treatment.
Dr. Pegram is SO amazing!
A fine person and always helpful. The BEST!!
NOT NP. Dr. Pegram is a very good listener and comes across as caring and invested in my recovery. Same w/Emily Storey - I feel like I am n good hands.
Dr. Pegram is absolutely AMAZING!! He made me feel at ease and I was thoroughly happy with his guidance. Stanford is blessed to have such an accomplished dr.
Dr. Pegram is the best doctor I have ever had. He is thorough, kind and just nice.
The oncologist is great and very knowledgeable in his field. I feel there are so many patients though and the care is not as personable and there's no one-on-one. I usually need to follow up with blood orders & test results and explanations of the results.
The breast cancer oncology team is wonderful caring skilled - an excellent experience in spite of the cancer.
Exceptional for ALL care givers.
Bernie is amazing, friendly, helpful.
Just terrific care.
Love Dr. Pegram. Would recommend him but would make sure referral understands he is NEVER timely.
Dr. Pegram made the final decision about my care.
Dr. Pegram saved my life. He recognized a pending heart problem - sent me to emergency where I had a cardiac arrest! He was on the ball 100%
Dr. Pegram is very knowledgeable, kind and compassionate. He has given me the confidence to continue to fight my cancer.
Dr. Pegram & his staff are always very thorough and take time to listen to my questions & concerns, if any.
Didn't have time to answer questions in some cases answered a related question, not the one I asked.
Dr. Pegram rocks! He is caring. Very knowledgeable, inspires confidence, astute.
Anything negative is far overshadowed by all the GOOD received from Dr. Pegram!!
I come all the way from Petaluma because I feel that I have a better chance of living longer because of Stanford providers.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:Ìý1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
ÌÇÐÄ´«Ã½ provides comprehensive services toÌýreferÌýandÌýtrack patients, as well as the latest information and news for physicians and office staff.ÌýFor help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
Ìý
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records